Endoplast ApS: Financial statements 2022
CVR: 40866442
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Endoplast ApS (CVR 40866442) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -462,598 and a net result of DKK -375,524 compared with DKK -89,292 the year before. Equity in the 2022 report amounted to DKK -403,574.
- Gross Profit
- DKK -462,598
- Profit/Loss
- DKK -375,524
- Equity
- DKK -403,574
- Total Assets
- DKK 283,130
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -463 t. | -376 t. | -404 t. | 0 |
| 2021 | - | -109 t. | -89 t. | -28 t. | 0 |
Official annual report
Keep an eye on Endoplast ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Endoplast ApS has published its annual report for 2021. Gross profit came to DKK -108,862, and the net result was DKK -89,292.
About Endoplast ApS
Endoplast ApS is a Danish company of the type Anpartsselskab based in Hårlev, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Thomas Foldberg. The company is owned by TACC Holding ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK 168,968 and a net result of DKK 99,945 compared with DKK -19,064 the year before. Equity in the 2025 report amounted to DKK -268,595.